A Nonrandomized Phase 2 Trial of EG-Mirotin, a Novel, First-in-Class, Subcutaneously Deliverable Peptide Drug for Nonproliferative Diabetic Retinopathy

Background and objectives: EG-Mirotin (active ingredient EGT022) targets nonproliferative diabetic retinopathy (NPDR), the early stage of retinopathy. EG-Mirotin reverses capillary damage before NPDR progresses to an irreversible stage. EG-Mirotin safety and efficacy were investigated in patients wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Yoo, Seunghoon, You, Dae Hyuk, Lee, Jeongyoon, Hong, H. Christian, Lee, Sung Jin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9862301/
https://www.ncbi.nlm.nih.gov/pubmed/36676801
http://dx.doi.org/10.3390/medicina59010178

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9862301/
https://www.ncbi.nlm.nih.gov/pubmed/36676801
http://dx.doi.org/10.3390/medicina59010178

Ejemplares similares